PMID- 35231746
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20220426
IS  - 1872-8464 (Electronic)
IS  - 0165-5876 (Linking)
VI  - 156
DP  - 2022 May
TI  - Antibiotic adverse effects in pediatric acute rhinosinusitis: Systematic review 
      and meta-analysis.
PG  - 111064
LID - S0165-5876(22)00025-8 [pii]
LID - 10.1016/j.ijporl.2022.111064 [doi]
AB  - BACKGROUND: Pediatric acute bacterial rhinosinusitis (ABRS) is often treated with 
      oral antibiotics, with limited insight into adverse effects (AEs) across drug 
      classes. In this systematic review and meta-analysis, we characterize AE 
      incidence associated with oral antibiotics in these patients. 
      METHODOLOGY/PRINCIPAL: We searched PubMed and Embase for English-language 
      articles published from 1985 to September 2020 reporting AEs of oral antibiotic 
      therapy for ABRS patients aged 0-18 years. Six-hundred and sixty-six articles 
      underwent title and abstract screening, identifying 154 articles for full-length 
      review. RESULTS: Eleven articles were included, most of which reported individual 
      and aggregate AE incidences. Amoxicillin/clavulanate, amoxicillin, 
      cephalosporin/carbacephem, and placebo groups were identified. Random-effects 
      meta-analysis of prospective groups identified appreciable incidences of diarrhea 
      and abdominal pain, and low incidence of rash, for amoxicillin-clavulanate and 
      amoxicillin. All antibiotics as well as placebo were associated with non-zero 
      overall AE incidence. Children receiving antibiotics were about twice as likely 
      to incur any AE during treatment in placebo-controlled studies, though this 
      association was not significant. High heterogeneity limited most point estimates, 
      with risk of bias, typically in outcomes measurement, detected in most studies. 
      CONCLUSIONS: Reporting of AEs associated with oral antibiotic use in pediatric 
      ABRS is limited in current literature. Adverse effects are non-negligible, but 
      may not significantly exceed placebo.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Axiotakis, Lucas G Jr
AU  - Axiotakis LG Jr
AD  - Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos 
      College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University 
      Irving Medical Center, New York, NY, USA.
FAU - Szeto, Betsy
AU  - Szeto B
AD  - Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos 
      College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University 
      Irving Medical Center, New York, NY, USA.
FAU - Gonzalez, Joseph N
AU  - Gonzalez JN
AD  - Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos 
      College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University 
      Irving Medical Center, New York, NY, USA.
FAU - Caruana, Francesco F
AU  - Caruana FF
AD  - Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos 
      College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University 
      Irving Medical Center, New York, NY, USA.
FAU - Gudis, David A
AU  - Gudis DA
AD  - Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos 
      College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University 
      Irving Medical Center, New York, NY, USA.
FAU - Overdevest, Jonathan B
AU  - Overdevest JB
AD  - Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos 
      College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University 
      Irving Medical Center, New York, NY, USA. Electronic address: 
      j.overdevest@columbia.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220216
PL  - Ireland
TA  - Int J Pediatr Otorhinolaryngol
JT  - International journal of pediatric otorhinolaryngology
JID - 8003603
RN  - 0 (Anti-Bacterial Agents)
RN  - 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination)
RN  - 804826J2HU (Amoxicillin)
SB  - IM
MH  - Acute Disease
MH  - Amoxicillin/adverse effects
MH  - Amoxicillin-Potassium Clavulanate Combination/adverse effects
MH  - Anti-Bacterial Agents/adverse effects
MH  - Child
MH  - Humans
MH  - Prospective Studies
MH  - *Sinusitis/drug therapy
OTO - NOTNLM
OT  - Adverse effects
OT  - Anti-bacterial agents
OT  - Antibiotics
OT  - Meta-analysis
OT  - Pediatrics
OT  - Sinusitis
EDAT- 2022/03/02 06:00
MHDA- 2022/04/27 06:00
CRDT- 2022/03/01 20:15
PHST- 2021/09/02 00:00 [received]
PHST- 2022/02/12 00:00 [accepted]
PHST- 2022/03/02 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2022/03/01 20:15 [entrez]
AID - S0165-5876(22)00025-8 [pii]
AID - 10.1016/j.ijporl.2022.111064 [doi]
PST - ppublish
SO  - Int J Pediatr Otorhinolaryngol. 2022 May;156:111064. doi: 
      10.1016/j.ijporl.2022.111064. Epub 2022 Feb 16.